CTLA4 and non-small cell lung carcinoma: In another phase III trial (MYSTIC) offrontline therapy in patients with NSCLC, durvalumab monotherapy is being comparedwith either a combination of durvalumab plus the anti-CTLA-4 antibody tremelimumabor standard-of-care chemotherapy [ClinicalTrials.gov identifier: NCT02453282].